Method for mammoplasty

FIELD: medicine.

SUBSTANCE: mammary gland (MG) plasty with high ptosis or a stretched "dermal sheath" is performed. At that, Botox is injected into the large pectoral muscle 8-10 days before the operation and into the cavity in the large pectoral muscle base during the operation, prior to implant insertion. During the operation, the MG skin within the operating field is shrunk by exposure to laser radiation or ultrasound. Fibrin glue mixed with a solution of a nonpolarizing muscle relaxant is used, and the cavity is washed with an antibiotic solution before drying.

EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, minimizes ptosis, excludes scars on the incision site.

3 cl, 14 dwg, 3 tbl, 3 ex



Same patents:

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine.

SUBSTANCE: invention aims at treating drug-induced dry eye syndrome (DI-DES). Treating DI-DES implies taking the past medical history, measuring tear production and eye xerosis values reduced and increased respectively in relation to the norm. Unpreserved ocular hypotensive medications are prescribed in the patient. Unpreserved artificial tears are also applied. The lachrymal fluid is analysed by a multicytokine technique. If the analysis shows increased concentrations of proinflammatory cytokines - interleukin-6, interleukin-8, interleukin-12, Th-1 - interleukin-2, interferon-gamma, and Th-2 - interleukin-4, by min 30% in relation to the patient's age norm, a chronic immune ocular inflammation is detected. That requires transpalpebral Blepharogel-1 phonophoresis and 1% hydrocortisone ointment phonophoresis on the sub-mastoidal region from both sides; the therapeutic course is 8-10 daily procedures.

EFFECT: optimal conditions for diagnosing and reasoned differentiated therapy of DI-DES that enables prescribing the pathogenetically reasoned therapy in due time and increasing the efficacy of the therapeutic exposure.

1 tbl, 2 ex

FIELD: physics.

SUBSTANCE: mechanism (100, 200, 310) of positioning of high-intensity focused ultrasound for positioning of radiator (292, 304) of high-intensity focused ultrasound. Note here that said mechanism comprises positioning plate (108, 308) to house radiator of high-intensity focused ultrasound, mechanism support (174) to accommodate positioning mechanism and multiple rods (110, 112, 114, 116, 118, 120, 210, 212, 214, 216, 218, 220). Note here that every rod has first and second ends. Note here that first end of every rod make a separate ball joint (122, 124, 126, 128, 130, 132, 222, 224, 226, 228, 230, 232) with positioning plate. Note here that multiple linear drives (146, 148, 150, 246, 248, 250, 252, 254) are mounted at mechanism support. Note also that every linear drive comprises drive unit (164, 166, 168, 264, 266, 268, 270, 272). Note here that second end of every rod make a separate ball joint (134, 136, 138, 140, 142, 144, 234, 236, 238, 240, 242, 244) with one of drive units.

EFFECT: development of mechanism of positioning of high-intensity focused ultrasound.

13 cl, 12 dwg

FIELD: medicine.

SUBSTANCE: orthopaedic unload is accompanied with prescribing a therapeutic diet promoting weight reduction and adequate feeding of calcium and vitamins C, D, E, K.That is combined with the oral administration of Fosamax® tablets 70 mg once a week for 6 months, Arthrodarin® capsules 50 mg in the morning and evening for 4-6 months and nasal sprayings of Miacalcic® 200 International Units/day in cycles of 2 weeks every 2 weeks for 4-6 months. What is also used is Milgamma® solution for intramuscular injections 2 ml a day, at least 10 times, with a pause of 1 day. Alflutop® 2 ml a day is injected intramuscularly daily within at least 20 days. That is combined with a therapeutic course including 8-10 therapeutic sessions each of which consists of the two stages of procedures following each other. The first of this stages involve the successive one-day abdominal decompression of the lower body from the waist down, pneumocompression massage of legs, manual and vacuum massages. The exposure segments are: hip joints - lateral surface of hips, gluteal region and paravertebral area L2-L5, cervical segment - paravertebral area C7-T1 and sacral bone. A preferred pause between the above procedures is no more than 10-15 minutes. Thereafter, the first stage of the therapeutic session is completed by conducting a hirudotherapy with the use of no more than 8 medicinal leeches per one session to be placed on the cervical paravertebral area C7-T1 and lumbar paravertebral area L2-L5, sacral bone, tail bone, abdomen within the liver, lower abdomen, painful hip segments and/or segments discoloured after the massage. Each therapeutic session is completed by successive procedures of the second stage with a pause of at least 3 days. A magnetic therapy and a barolasertherapy cover the segments: hip joints - lateral surface of hips, gluteal region and paravertebral areas L2-L5. A phonophoresis with the used of karipain gel covers the gluteal, knee and hip segments. Thereafter, 24 hours later the therapeutic session is repeated depending on the patient's state no more than 10 times. That is followed by doing therapeutic physical exercises in the swimming pool within at least 10 days. Kartalax® peptide preparation 1-2 ml in the concentration of at least 100 mcg in 1 ml diluted together with Tymalin® 10 mg is administered daily once a day for 10 days. After the injections are completed, peptide Vezugen® capsules 0.2 g are orally administered in the morning and in the evening 10-15 minutes before meals for 30 days. After the continuous and single course of Fosamax® and nasal sprayings of Miacalcic® are completed, 1-2 months later Osteogenon® tablets 830 mg are administered daily in a dose of 2-4 tablets 2 times a day, and Arthrodarin® capsules are also taken in a dose of 50 mg in the morning and in the evening for 4-6 months. The oral administration of the last-mentioned two preparations is repeated at least three months later.

EFFECT: preventing bone absorption and loss, restoring the shape, volume and normal consistence of an intraarticular cartilage that makes it possible to avoid the further progression of the disease and a necessity of surgical management in this group of patients.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves doing therapeutic exercises and pulsed ultrasonic therapy at a pulse length of 10 ms. That is combined with the magnetic stimulation of the shoulder girdle muscles: m. trapezius m. deltoideus, m. supraspinatus, m. infraspinatus on the involved side. That involves the exposure in accordance with a stable technique with using paired pulses of the length of 220±20 mcs at a pulse repetition frequency of 25±5 pulse/min and a pulse-to-pulse spacing of 80 ms for 3 min per one field. The exposure intensity is 70-90% of the maximum magnetic induction amplitude 1,300 mT. The total length of the procedure is 12 minutes. Then 30 minutes later, mud therapy is conducted by applications on the involved shoulder joint. A mud cake temperature makes 38-40 degrees, and the length of the exposure makes 20 minutes. The mud therapy is followed by ultrasonic therapy. The exposure covers the rotator cuff and attachment points of the tendons - m. supraspinatus, m. infraspinatus, m. teres minor on the involved side. The exposure follows a labile technique at an intensity of 0.2-0.4 W/cm2 for 2 minutes per each field at the total length of the procedure of 8 minutes. The procedures are daily. The therapeutic course is 8-10 procedures.

EFFECT: method enables clinical effectiveness by recovering the motor activity of the involved extremity and prolongs the remission, prevents the progression of the biomechanical and neurodystrophic disorders, and formation of neurological complications.

1 ex, 4 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves performing the following stages: - treating a nerve canal with sodium hypochlorite in the concentration of 0.5-5.25 wt %, in an amount of 1-20 ml for one root canal and activating with ultrasound at frequency 20-40 kHz; both one-stage activation with ultrasound accompanying the treatment, and alternating the sodium hypochlorite treatment and activation with ultrasound every 3-5 sec are possible, - treating with ozonised normal saline in the ozone concentration of 10 mcg to 60 mg per one litre, in an amount of 1-20 ml per 1 root canal and activating with ultrasound at frequency 20-40 kHz, - treating with aqueous chlorhexidine in the concentration of 0.12-2 wt %, in an amount of 1-20 ml per one root canal and activating with ultrasound at frequency 20-40 kHz; the above stages are intermitted with time intervals of no more than 3 minutes, and each stage lasts for 3 to 15 minutes.

EFFECT: high quality of treatment by preventing a post-filling aggravation and reducing the length of periodontal tissue regeneration; the method is easy-to-implement and efficient.

2 ex

FIELD: medicine.

SUBSTANCE: method involves an endoural ultrasonic exposure covering the middle ear tissues with the use of a therapeutic agent used as a medium; the medium is presented with solution of thiamphenicol glycinate acetylcisteinate. The ultrasonic exposure is generated at oscillating amplitude 40 mcm, frequency 26.5 kHz and length 15 sec with the course of 7 procedures performed daily.

EFFECT: method enables providing the higher therapeutic effectiveness in secretory otitis media by using the declared parameters of the ultrasonic exposure enabling to avoid injuries of the middle ear tissues, as well as providing higher bioavailability of the preparation possessing the wide spectrum of antibacterial preparation, antiadhesive, antioxidant, anti-inflammatory action.

1 ex

FIELD: medicine.

SUBSTANCE: cochlea is exposed to contact ultrasonic radiation (UR) through a postaural surface of the individual's head. Ultrasound amplitude is modulated by electric signal generated by microphone sound receiver. The microphone is arranged close to an ultrasonic transmitter providing the binarual effect. The electric output signals of the microphone are filtered within the frequency range of 0.5÷5 kHz; an ultrasonic oscillation frequency is set at a value of at least 100 kHz; an ultrasound intensity is set at a value of no more than 0.1 Wt/cm2; a radiation pressure is generated in the cochlea of not less than 2·10-4 Pa.

EFFECT: method enables restoring the sound sensation and compensating the middle ear dysfunction that is ensured by ultrasound modulation by the audio signal generated by the microphone and providing the required pressure in the cochlea.

2 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves a course of 5-7 pulse ultrasonic procedures having an intensity of 0.2-0.4 W/cm2 of 5-7 minutes daily. That is combined with enzyme therapy with Longidaza 3,000 units 2 times a week for 1 month. Besides, Trilon B rectal suppositories 1,000 mg and Dimexidum 200 mg are administered daily for the night for 3 months. The bacteria are detected by a microscopic and microbiologic examination of ejaculate that is followed by a 4-6-week antibacterial therapy by administering an antibacterial preparation taking into account the microflora sensitivity.

EFFECT: such implementation of the method provides removing the prostate stones or decreasing the number thereof, reducing a probability of the inflammatory process in the prostate, ensuring a differentiated therapeutic approach by detecting the group of patients whom the antibacterial therapy is indicated to.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: device for the endoluminal treatment of a blood vessel comprises a flexible wave guide with a light guide tube. The wave guide has an elongated axis, a proximal end with a connector for optical connection to a laser light source, a distal end placed in the blood vessel and comprising an emitting surface for the emission of light from the light source sideways in relation to the elongated axis of the wave guide onto a surrounding vascular wall segment extending within the angular range. The device is provided with a secondary laser light source, a reflected light reception detector, a laser light transparent cone-shaped primary diffuser (1) with laser light deflection and a secondary diffuser (3) extending the laser light coverage area. The primary diffuser (1) is mounted at an optical output of the wave guide between the emitting surface of the wave guide and a sapphire safety cap (2). The secondary diffuser (3) is mounted between the safety cap (2) and the primary diffuser (1). The device also comprises a detachable sterilised protective sheath (4). The protective sheath (4) is made from heat-shrinkage polytetrafluoroethylene, configured as a tube with an ultrasound contrast insert and mounted on the wave guide over the safety cap (2).

EFFECT: using the invention is expected to improve the quality of blood vessel coagulation, eliminating light guide burning and reducing its friction on the blood vessel.

2 cl, 3 dwg